203 related articles for article (PubMed ID: 31904261)
1. A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy.
Wang T; Zhou J; Tian S; Wang Y; Patel P; Jani AB; Langen KM; Curran WJ; Liu T; Yang X
Br J Radiol; 2020 Mar; 93(1107):20190845. PubMed ID: 31904261
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy.
Wang T; Press RH; Giles M; Jani AB; Rossi P; Lei Y; Curran WJ; Patel P; Liu T; Yang X
Br J Radiol; 2019 May; 92(1097):20190089. PubMed ID: 30912959
[TBL] [Abstract][Full Text] [Related]
3. Prostate stereotactic ablative radiation therapy using volumetric modulated arc therapy to dominant intraprostatic lesions.
Murray LJ; Lilley J; Thompson CM; Cosgrove V; Mason J; Sykes J; Franks K; Sebag-Montefiore D; Henry AM
Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):406-15. PubMed ID: 24685447
[TBL] [Abstract][Full Text] [Related]
4. Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study.
Ong ALK; Knight K; Panettieri V; Dimmock M; Tuan JKL; Tan HQ; Wright C
Front Oncol; 2023; 13():1241711. PubMed ID: 38023170
[TBL] [Abstract][Full Text] [Related]
5. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
van Lin EN; Fütterer JJ; Heijmink SW; van der Vight LP; Hoffmann AL; van Kollenburg P; Huisman HJ; Scheenen TW; Witjes JA; Leer JW; Barentsz JO; Visser AG
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):291-303. PubMed ID: 16618584
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of dominant intraprostatic lesion boosting using advanced photon-, proton- or brachytherapy.
Andrzejewski P; Kuess P; Knäusl B; Pinker K; Georg P; Knoth J; Berger D; Kirisits C; Goldner G; Helbich T; Pötter R; Georg D
Radiother Oncol; 2015 Dec; 117(3):509-14. PubMed ID: 26349588
[TBL] [Abstract][Full Text] [Related]
7. Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging.
Pouliot J; Kim Y; Lessard E; Hsu IC; Vigneron DB; Kurhanewicz J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1196-207. PubMed ID: 15234056
[TBL] [Abstract][Full Text] [Related]
8. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
[TBL] [Abstract][Full Text] [Related]
9. Effect on therapeutic ratio of planning a boosted radiotherapy dose to the dominant intraprostatic tumour lesion within the prostate based on multifunctional MR parameters.
Riches SF; Payne GS; Desouza NM; Dearnaley D; Morgan VA; Morgan SC; Partridge M
Br J Radiol; 2014 May; 87(1037):20130813. PubMed ID: 24601648
[TBL] [Abstract][Full Text] [Related]
10. Helical tomotherapy and intensity modulated proton therapy in the treatment of dominant intraprostatic lesion: a treament planning comparison.
Fellin F; Azzeroni R; Maggio A; Lorentini S; Cozzarini C; Di Muzio N; Fiorino C; Calandrino R; Schwarz M
Radiother Oncol; 2013 May; 107(2):207-12. PubMed ID: 23541644
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study.
Kim YJ; Yoon KJ; Kim YS
Sci Rep; 2020 Sep; 10(1):14713. PubMed ID: 32895442
[TBL] [Abstract][Full Text] [Related]
12. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
13. Ultrahypofractionated radiotherapy for localized prostate cancer with simultaneous boost to the dominant intraprostatic lesion: a plan comparison.
Cambria R; Ciardo D; Bazani A; Pansini F; Rondi E; Maestri D; Zerini D; Marvaso G; Romanelli P; Timon G; Fodor C; Petralia G; Alessi S; Pricolo P; Vischioni B; Fossati P; Molinelli S; Russo S; Ciocca M; De Cobelli O; Renne G; Orecchia R; Cattani F; Jereczek-Fossa BA
Tumori; 2022 Jun; 108(3):263-269. PubMed ID: 33896239
[TBL] [Abstract][Full Text] [Related]
14. Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts.
Goodman CD; Fakir H; Pautler S; Chin J; Bauman GS
Adv Radiat Oncol; 2020; 5(2):212-220. PubMed ID: 32280821
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous integrated boost (SIB) to dominant intra-prostatic lesions during extreme hypofractionation for prostate cancer: the impact of rectal spacers.
Osman SOS; Fairmichael C; Whitten G; Lundy GS; Wesselman R; Wilson ML; Hounsell AR; Prise KM; Irvine D; McGarry CK; Jain S
Radiat Oncol; 2022 Feb; 17(1):38. PubMed ID: 35193630
[TBL] [Abstract][Full Text] [Related]
16. Cone beam CT-based dose accumulation and analysis of delivered dose to the dominant intraprostatic lesion in primary radiotherapy of prostate cancer.
Tamihardja J; Cirsi S; Kessler P; Razinskas G; Exner F; Richter A; Polat B; Flentje M
Radiat Oncol; 2021 Oct; 16(1):205. PubMed ID: 34702305
[TBL] [Abstract][Full Text] [Related]
17. The feasibility of a dose painting procedure to treat prostate cancer based on mpMR images and hierarchical clustering.
Rezaeijo SM; Hashemi B; Mofid B; Bakhshandeh M; Mahdavi A; Hashemi MS
Radiat Oncol; 2021 Sep; 16(1):182. PubMed ID: 34544468
[TBL] [Abstract][Full Text] [Related]
18. Proton vs. photon radiotherapy for MR-guided dose escalation of intraprostatic lesions.
Moteabbed M; Harisinghani M; Paganetti H; Trofimov A; Lu HM; Efstathiou JA
Acta Oncol; 2021 Oct; 60(10):1283-1290. PubMed ID: 34282708
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy.
Shaaer A; Paudel M; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
Brachytherapy; 2020; 19(5):599-606. PubMed ID: 32712028
[TBL] [Abstract][Full Text] [Related]
20. Volumetric modulated arc therapy planning for primary prostate cancer with selective intraprostatic boost determined by 18F-choline PET/CT.
Kuang Y; Wu L; Hirata E; Miyazaki K; Sato M; Kwee SA
Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):1017-25. PubMed ID: 25832692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
